DUBLIN, April 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2025 first quarter financial results and provide a business and financial update.  Audio webcast/conference call:U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926A ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estim ...

Jazz Pharmaceuticals (JAZZ) shares soared 7.1% in the last trading session to close at $110.12. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 24.9% loss over the past four weeks.The rise in share price came after President Trump announced a 90-day pause on his sweeping tariffs against non-retaliating countries.This drugmaker is expected to post quarterly earnings of $4.65 per share in its upcoming report, which represents a yea ...

JAZZ currently has a forward P/E ratio of 5.27, while ARGX has a forward P/E of 47.10. We also note that JAZZ has a PEG ratio of 0.72. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ARGX currently has a PEG ratio of 1.45. Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX) . But which of these two companies ...

DUBLIN, March 26, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 24th Annual Needham Healthcare Conference. Company management will participate in a fireside chat on Wednesday, April 9, 2025, at 9:45 a.m. PT / 12:45 p.m. ET / 5:45 p.m. IST.An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Sco ...

Core Viewpoint - Jazz Pharmaceuticals (JAZZ) shares have increased by 3% over the past four weeks, closing at $139.51, with a potential upside of 38.9% based on Wall Street analysts' mean price target of $193.83 [1] Price Targets - The average of 18 short-term price targets ranges from a low of $150 to a high of $230, with a standard deviation of $23.90, indicating variability among analysts [2] - The lowest estimate suggests a 7.5% increase from the current price, while the highest estimate indicates a 64.9% upside [2] Analyst Sentiment - Analysts show strong agreement on JAZZ's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - The Zacks Consensus Estimate for the current year has risen by 10.5% over the past month, with nine estimates increasing and two decreasing [10] Zacks Rank - JAZZ holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11] Earnings Estimate Revisions - There is a strong correlation between trends in earnings estimate revisions and near-term stock price movements, suggesting that the positive revisions could indicate an upside for JAZZ [9]

Updated top-line results demonstrate improved outcomes in adults with narcolepsy or idiopathic hypersomnia treated with Xywav as observed in the Phase 4 DUET (Developing Understanding of Hypersomnia by Evaluating Low-Sodium Oxybate Treatment) studyNovel analysis of real-world Epidiolex treatment patterns underscore importance of dose optimization for improved patient persistenceFor U.S. media and investors onlyDUBLIN, March 19, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced tha ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Illumina (ILMN) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on ear ...

Core Insights - Zacks Premium provides tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators that help investors select stocks likely to outperform the market in the next 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Value Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [3] - The Growth Score assesses a company's financial health and future outlook through projected and historical earnings, sales, and cash flow [4] - The Momentum Score identifies optimal times to invest based on price trends and earnings estimate changes [5] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7][8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B to maximize returns [9] Stock Highlight: Jazz Pharmaceuticals - Jazz Pharmaceuticals, based in Dublin, is a specialty biopharmaceutical company focusing on neuroscience and oncology, currently holding a Zacks Rank of 2 (Buy) and a VGM Score of A [11] - The company has a forward P/E ratio of 5.88, indicating strong value metrics, and has seen nine analysts revise earnings estimates higher for fiscal 2025, with the consensus estimate rising by $1.09 to $23.15 per share [12]